Breborowicz Anna, Niedziela Marek
Department of Pediatric Pneumonology, Allergology and Clinical Immunology, Poznan University of Medical Sciences, Poland.
J Pediatr Endocrinol Metab. 2007 Jul;20(7):781-9. doi: 10.1515/jpem.2007.20.7.781.
A number of previous studies have suggested that adrenal suppression occurs in asthmatic children treated with high-doses of inhaled glucocorticoids (IGC). This study was designed to determine the frequency of adrenal suppression in children with severe asthma treated with recommended doses of IGC: namely 500-1,000 microg/day of fluticasone propionate or the equivalent of budesonide (1,000-2,000 microg/day) for a period of at least 12 months.
Early morning cortisol (F) and ACTH serum levels were measured in 27 severe asthmatics aged 6-16 years old. The children underwent a low dose ACTH test (1 microg/1.73 m2) with a parallel glucose measurement. Twenty-four hour urine collection was performed before examination for free F (UfF) and creatinine levels. There were no clinical manifestations of adrenal hypofunction in the analyzed children.
Of the 27 patients, 22 had normal basal and post-stimulatory levels of F and normal UfF, and the other five (18.5%) had basal serum F levels of <400 nmol/l. Four of the five also had normal post-stimulatory levels of F and normal UfF. One child had a subnormal peak F value of 484 nmol/l during the ACTH test. None of the patients had a suppressed serum ACTH level, but an elevated ACTH level was found in four children. This study provided biochemical evidence of suboptimal adrenal function in one child in the examined group (3.7%) and a good response to stimulation in all the others, even in those with slightly reduced basal cortisol levels.
This study showed that the use of fluticasone in doses of up to 1,000 microg/day (or the equivalent of budesonide) as long-term treatment of children with severe asthma did not substantially affect their adrenal function.
此前多项研究表明,接受高剂量吸入糖皮质激素(IGC)治疗的哮喘儿童会出现肾上腺抑制。本研究旨在确定接受推荐剂量IGC治疗的重度哮喘儿童肾上腺抑制的发生率:即丙酸氟替卡松500 - 1000微克/天或等效布地奈德(1000 - 2000微克/天),治疗期至少12个月。
对27名6 - 16岁的重度哮喘患儿测定清晨皮质醇(F)和促肾上腺皮质激素(ACTH)血清水平。患儿接受低剂量ACTH试验(1微克/1.73平方米)并同时测量血糖。检查前进行24小时尿游离F(UfF)和肌酐水平收集。分析的患儿均无肾上腺功能减退的临床表现。
27例患者中,22例F的基础和刺激后水平正常且UfF正常,另外5例(18.5%)基础血清F水平<400纳摩尔/升。这5例中的4例F刺激后水平和UfF也正常。1名儿童在ACTH试验期间F峰值低于正常,为484纳摩尔/升。所有患者血清ACTH水平均未受抑制,但4名儿童ACTH水平升高。本研究提供了生化证据,表明检查组中有1名儿童(3.7%)肾上腺功能未达最佳状态,其他所有儿童对刺激反应良好,即使是基础皮质醇水平略有降低的儿童。
本研究表明,使用高达1000微克/天的氟替卡松(或等效布地奈德)长期治疗重度哮喘儿童,对其肾上腺功能无实质性影响。